Home Newsfeeds PennyMac Financial Servs Q2 EPS $2.28 Down From $2.94 YoY

PennyMac Financial Servs Q2 EPS $2.28 Down From $2.94 YoY

PennyMac Financial Servs (NYSE:PFSI) reported quarterly earnings of $2.28 per share. This is a 22.45 percent decrease over earnings of $2.94 per share from the same period last year.

byBenzinga Newsdesk

August 2, 2022

1 minute read

PennyMac Financial Servs (NYSE:PFSI) reported quarterly earnings of $2.28 per share. This is a 22.45 percent decrease over earnings of $2.94 per share from the same period last year.

Cathie Wood Buys More Meta Shares As Mark Zuckerberg Goes All-In On Twitter Rivalry

By Benzinga Newsbot

July 7, 1:59 AM

On Thursday, Cathie Wood-led Ark Invest made several trades, the most prominent of which was a significant purchase…

ARKW

Cautious Optimism For Bluebird Bio’s Sickle Cell Therapy: Analyst Sees Financial Challenges

By Vandana Singh

October 17, 2:40 PM

Cantor Fitzgerald initiated coverage on Bluebird Bio Inc (NASDAQ: BLUE), saying sickle cell disorder (SCD) has been a hotbed of development for genetic medicines as the company's lovo-cel marches towards the U.S. market.

BLUE

Actinium Pharma Highlights Six Abstracts Accepted For Oral And Poster Presentation At The SNMMI 2023 Annual Meeting

By Benzinga Newsdesk

June 23, 8:05 AM

Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today details the six abstracts accepted for oral and poster presentation at the upcoming

ATNM

Cisco Q1 Earnings: Weak Guidance Overshadows Top- And Bottom-Line Beat As New Product Orders Slow

By Adam Eckert

November 15, 5:32 PM

Cisco Systems Inc (NASDAQ: CSCO) reported fiscal first-quarter financial results after the close on Wednesday.

CSCO

PennyMac Financial Servs Q2 EPS $2.28 Down From $2.94 YoY

Related Posts

Cathie Wood Buys More Meta Shares As Mark Zuckerberg Goes All-In On Twitter Rivalry

Cautious Optimism For Bluebird Bio’s Sickle Cell Therapy: Analyst Sees Financial Challenges

Actinium Pharma Highlights Six Abstracts Accepted For Oral And Poster Presentation At The SNMMI 2023 Annual Meeting

Cisco Q1 Earnings: Weak Guidance Overshadows Top- And Bottom-Line Beat As New Product Orders Slow